UA112446C2 - Застосування омега-жирних кислот для лікування захворювання - Google Patents
Застосування омега-жирних кислот для лікування захворюванняInfo
- Publication number
- UA112446C2 UA112446C2 UAA201402331A UAA201402331A UA112446C2 UA 112446 C2 UA112446 C2 UA 112446C2 UA A201402331 A UAA201402331 A UA A201402331A UA A201402331 A UAA201402331 A UA A201402331A UA 112446 C2 UA112446 C2 UA 112446C2
- Authority
- UA
- Ukraine
- Prior art keywords
- mmol
- docosahexaenoic acid
- acid
- dosage
- omega
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract 8
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 4
- 229940090949 docosahexaenoic acid Drugs 0.000 abstract 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 4
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 abstract 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 abstract 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000008961 swelling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Винахід стосується способу лікування та/або запобігання стану, при якому вводять ейкозапентаєнову кислоту (ЕПК) і докозагексаєнову кислоту (ДГК) або їх сіль, або складний ефір, об'єкту, що цього потребує, при цьому згаданий стан вибраний з групи, що включає набряк жовтої плями, стани, що викликають пошкодження фоторецепторів сітківки та/або клітин пігментного епітелію сітківки і сухість очей у ссавців, комбіноване дозування ейкозапентаєнової кислоти і докозагексаєнової кислоти становить від 5 ммоль до 25 ммоль на добу, а молярне відношення ейкозапентаєнової кислоти до докозагексаєнової кислоти становить від 1:1 до 5:1, дозування ейкозапентаєнової кислоти становить від 4 ммоль до 15 ммоль на добу, а дозування докозагексаєнової кислоти становить від 2 ммоль до 7,5 ммоль на добу.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11390001 | 2011-09-12 | ||
| PCT/EP2012/067771 WO2013037794A1 (en) | 2011-09-12 | 2012-09-12 | Use of omega fatty acids for treating disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA112446C2 true UA112446C2 (uk) | 2016-09-12 |
Family
ID=47040651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201402331A UA112446C2 (uk) | 2011-09-12 | 2012-12-09 | Застосування омега-жирних кислот для лікування захворювання |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9314445B2 (uk) |
| EP (1) | EP2755647B1 (uk) |
| JP (1) | JP2016508955A (uk) |
| KR (1) | KR101629670B1 (uk) |
| CN (2) | CN103998034A (uk) |
| AU (1) | AU2012307524B2 (uk) |
| BR (1) | BR112014005546A2 (uk) |
| CA (1) | CA2845868C (uk) |
| CO (1) | CO6910186A2 (uk) |
| CY (1) | CY1117280T1 (uk) |
| DK (1) | DK2755647T3 (uk) |
| ES (1) | ES2565402T3 (uk) |
| HR (1) | HRP20151039T1 (uk) |
| IL (1) | IL231374A (uk) |
| MX (1) | MX2014002877A (uk) |
| PH (1) | PH12014500510A1 (uk) |
| RU (1) | RU2589703C2 (uk) |
| SI (1) | SI2755647T1 (uk) |
| UA (1) | UA112446C2 (uk) |
| WO (1) | WO2013037794A1 (uk) |
| ZA (1) | ZA201402318B (uk) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160310456A1 (en) * | 2013-03-12 | 2016-10-27 | Physicians Recommended Nutriceuticals, Llc | Compositions and methods for using same for reducing levels of arachidonic acid in tissue having undergone an invasive procedure |
| US20210121430A1 (en) | 2011-07-18 | 2021-04-29 | Prn Physician Recommended Nutriceuticals, Llc | Omega-3 fatty acid supplementation for use in treating dry eye |
| US10709680B2 (en) | 2011-07-18 | 2020-07-14 | Physicians Recommended Nutriceuticals, Llc | Methods for treating dry eye |
| CN103998034A (zh) | 2011-09-12 | 2014-08-20 | 塔索斯·乔治欧 | ω脂肪酸用于治疗疾病的用途 |
| WO2014110261A1 (en) | 2013-01-11 | 2014-07-17 | Massachusetts Eye And Ear Infirmary | Cyp450 lipid metabolites reduce inflammation and angiogenesis |
| UA117274C2 (uk) * | 2013-12-19 | 2018-07-10 | Тасос Гєоргіу | Спосіб лікування, зменшення інтенсивності або профілактити захворювань, обумовлених ураженням зорового нерва |
| WO2015165507A1 (en) * | 2014-04-29 | 2015-11-05 | Georgiou Tassos | Treatment of eye diseases using omega 3 fatty acids and aa/epa blood ratio |
| CN108354919A (zh) * | 2017-12-29 | 2018-08-03 | 广东海洋大学 | 一种用于提高抗氧化功能的不饱和脂肪酸组合物及其应用 |
| CN108096181A (zh) * | 2018-02-05 | 2018-06-01 | 西安医学院 | Dha、epa在制备治疗干眼症的口服药物的应用 |
| BR112021003452A2 (pt) * | 2018-08-29 | 2021-05-18 | Cellix Bio Private Limited | composto e composição farmacêutica |
| CN115551498A (zh) * | 2020-03-11 | 2022-12-30 | 博士伦爱尔兰有限公司 | 包含极长链脂肪酸的用于眼睛健康的组合物和方法 |
| KR102409377B1 (ko) * | 2020-06-30 | 2022-06-17 | (주)에이앤바이오 | 반려동물용 눈 건조 개선 및 눈물 착색 예방을 위한 조성물 |
| KR20230158076A (ko) * | 2021-03-18 | 2023-11-17 | 제니비젼 인크. | 눈 질환을 치료하기 위한 방법 및 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0892129A (ja) * | 1993-10-08 | 1996-04-09 | Kanagawa Kagaku Kenkyusho:Kk | 眼発作治療薬 |
| US20040076695A1 (en) * | 2002-07-08 | 2004-04-22 | Advanced Vision Research | EPA and DHA enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
| US7887847B2 (en) * | 2004-05-08 | 2011-02-15 | Paul Jr Edward L | Nutritional supplement for treatment of ocular diseases |
| BRPI0512864B8 (pt) * | 2004-07-01 | 2021-05-25 | Johnson & Johnson Vision Care | composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição |
| EP1932521A1 (en) * | 2006-12-15 | 2008-06-18 | Novartis AG | Nutritional supplement composition for treatment of ocular diseases |
| PE20091462A1 (es) * | 2008-02-04 | 2009-10-23 | Novartis Ag | Composicion nutricional a base de vitaminas c y e, luteina, zinc, acidos grasos y cobre |
| US20090226547A1 (en) * | 2008-03-05 | 2009-09-10 | Gilbard Jeffrey P | Dietary Supplement For Eye Health |
| IT1393419B1 (it) | 2009-03-19 | 2012-04-20 | Medivis S R L | Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6. |
| CA2756528A1 (en) | 2009-04-17 | 2010-10-21 | Celavista Pharmaceuticals Limited | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
| US9381183B2 (en) | 2012-07-18 | 2016-07-05 | Physicians Recommended Nutriceuticals, Llc | Methods for improving the quality of the meibum composition of meibomian glands |
| CN103998034A (zh) | 2011-09-12 | 2014-08-20 | 塔索斯·乔治欧 | ω脂肪酸用于治疗疾病的用途 |
| WO2014110261A1 (en) | 2013-01-11 | 2014-07-17 | Massachusetts Eye And Ear Infirmary | Cyp450 lipid metabolites reduce inflammation and angiogenesis |
-
2012
- 2012-09-12 CN CN201280055590.7A patent/CN103998034A/zh active Pending
- 2012-09-12 DK DK12773237.8T patent/DK2755647T3/en active
- 2012-09-12 HR HRP20151039TT patent/HRP20151039T1/hr unknown
- 2012-09-12 JP JP2014529028A patent/JP2016508955A/ja active Pending
- 2012-09-12 CA CA2845868A patent/CA2845868C/en active Active
- 2012-09-12 US US14/343,863 patent/US9314445B2/en active Active
- 2012-09-12 SI SI201230324T patent/SI2755647T1/sl unknown
- 2012-09-12 ES ES12773237.8T patent/ES2565402T3/es active Active
- 2012-09-12 AU AU2012307524A patent/AU2012307524B2/en active Active
- 2012-09-12 RU RU2014113630/15A patent/RU2589703C2/ru active IP Right Revival
- 2012-09-12 KR KR1020147008179A patent/KR101629670B1/ko active Active
- 2012-09-12 EP EP12773237.8A patent/EP2755647B1/en active Active
- 2012-09-12 WO PCT/EP2012/067771 patent/WO2013037794A1/en not_active Ceased
- 2012-09-12 PH PH1/2014/500510A patent/PH12014500510A1/en unknown
- 2012-09-12 MX MX2014002877A patent/MX2014002877A/es active IP Right Grant
- 2012-09-12 BR BR112014005546A patent/BR112014005546A2/pt not_active Application Discontinuation
- 2012-09-12 CN CN201810856378.XA patent/CN108685890A/zh active Pending
- 2012-12-09 UA UAA201402331A patent/UA112446C2/uk unknown
-
2014
- 2014-03-06 IL IL231374A patent/IL231374A/en active IP Right Revival
- 2014-03-12 CO CO14053032A patent/CO6910186A2/es unknown
- 2014-03-28 ZA ZA2014/02318A patent/ZA201402318B/en unknown
-
2015
- 2015-11-18 CY CY20151101041T patent/CY1117280T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2565402T3 (es) | 2016-04-04 |
| BR112014005546A2 (pt) | 2017-03-21 |
| SI2755647T1 (sl) | 2015-11-30 |
| JP2016508955A (ja) | 2016-03-24 |
| KR101629670B1 (ko) | 2016-06-13 |
| RU2014113630A (ru) | 2015-10-20 |
| HRP20151039T1 (hr) | 2015-11-20 |
| PH12014500510A1 (en) | 2014-04-14 |
| WO2013037794A1 (en) | 2013-03-21 |
| NZ621321A (en) | 2015-09-25 |
| CN108685890A (zh) | 2018-10-23 |
| DK2755647T3 (en) | 2015-10-12 |
| CA2845868C (en) | 2018-11-06 |
| US20140227261A1 (en) | 2014-08-14 |
| RU2589703C2 (ru) | 2016-07-10 |
| CA2845868A1 (en) | 2013-03-21 |
| EP2755647B1 (en) | 2015-08-19 |
| US9314445B2 (en) | 2016-04-19 |
| AU2012307524B2 (en) | 2016-10-20 |
| IL231374A0 (en) | 2014-04-30 |
| EP2755647A1 (en) | 2014-07-23 |
| CY1117280T1 (el) | 2017-04-26 |
| MX2014002877A (es) | 2014-09-12 |
| AU2012307524A1 (en) | 2014-03-06 |
| CO6910186A2 (es) | 2014-03-31 |
| KR20140070569A (ko) | 2014-06-10 |
| ZA201402318B (en) | 2015-08-26 |
| CN103998034A (zh) | 2014-08-20 |
| IL231374A (en) | 2016-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA112446C2 (uk) | Застосування омега-жирних кислот для лікування захворювання | |
| CY1122629T1 (el) | Αιθυλεστερας εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας | |
| NZ702093A (en) | Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9) | |
| NZ757815A (en) | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | |
| PH12015502307A1 (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
| EA201590251A1 (ru) | Новые 5-аминотетрагидрохинолин-2-карбоновые кислоты и их применение | |
| NZ596228A (en) | Compositions and methods for the treatment of inflammation | |
| EA201591610A1 (ru) | Ингибиторы кинуренинового пути | |
| HK1204988A1 (en) | Methods and compositions for preventing or treating ophthalmic conditions | |
| BR112014011744A2 (pt) | formulação de ação sustentável da forma 2 de ciclosporina | |
| MX370361B (es) | Preparación farmacéutica que contiene compuesto de ácido piridilaminoacético. | |
| WO2015099838A3 (en) | Compositions and methods of treating ocular diseases | |
| EA201400067A1 (ru) | Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента | |
| HK1210417A1 (en) | Compositions, methods and/or devices for prevention and/or treatment of dry eye disorders | |
| MX2020002238A (es) | Composiciones de acidos grasos y ester de acido graso autoformadores de micelas y su uso en el tratamiento de patologias. | |
| RU2016129079A (ru) | Композиции омега-3 жирных кислот для лечения заболеваний, вызывающих поражение нервной системы | |
| CO6592101A2 (es) | Metodos para tratar ulceras de pie de diabetico | |
| RU2015112121A (ru) | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний | |
| AR092104A1 (es) | LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA) | |
| EA201690903A1 (ru) | Лечение глаукомы с использованием лаквинимода | |
| BR112013026644A2 (pt) | método para a modulação da atividade de citocina | |
| BR112014011336A2 (pt) | composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele | |
| EA201071350A1 (ru) | Композиции и способы для лечения воспаления роговицы | |
| MX2016013680A (es) | Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos. | |
| EP4257128A3 (en) | Methods and compounds for the treatment of genetic disease |